

Richard F Pollock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7120658/publications.pdf>

Version: 2024-02-01

52
papers

669
citations

687363

13
h-index

642732

23
g-index

52
all docs

52
docs citations

52
times ranked

851
citing authors

#	ARTICLE	IF	CITATIONS
1	The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. <i>Journal of Medical Economics</i> , 2022, 25, 393-402.	2.1	7
2	Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts. <i>Diabetes Therapy</i> , 2022, 13, 651-677.	2.5	0
3	Economic Analysis of Intravenous Iron in Patients with Iron Deficiency Anemia Due to Inflammatory Bowel Disease: Considerations for Clinicians [Letter]. <i>ClinicoEconomics and Outcomes Research</i> , 2022, Volume 14, 163-165.	1.9	0
4	Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose. <i>Journal of Medical Economics</i> , 2022, 25, 561-570.	2.1	4
5	A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 341-349.	2.4	6
6	Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 835-841.	1.9	0
7	An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 9-18.	1.9	9
8	Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2575-2587.	2.5	19
9	A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK. <i>Journal of Medical Economics</i> , 2020, 23, 1588-1597.	2.1	6
10	Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis. <i>Advances in Therapy</i> , 2020, 37, 4446-4457.	2.9	5
11	Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 997-1009.	2.4	4
12	A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. <i>Journal of Medical Economics</i> , 2020, 23, 751-759.	2.1	13
13	Impact of Stigma on People Living with Chronic Hepatitis B. <i>Patient Related Outcome Measures</i> , 2020, Volume 11, 95-107.	1.2	46
14	Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland. <i>Advances in Therapy</i> , 2020, 37, 1218-1232.	2.9	3
15	A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. <i>Journal of Medical Economics</i> , 2020, 23, 593-602.	2.1	10
16	Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. <i>Expert Review of Hematology</i> , 2020, 13, 187-195.	2.2	34
17	Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). <i>Applied Health Economics and Health Policy</i> , 2019, 17, 615-627.	2.1	10
18	A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. <i>Expert Review of Hematology</i> , 2019, 12, 129-136.	2.2	19

#	ARTICLE	IF	CITATIONS
19	Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. <i>Advances in Therapy</i> , 2019, 36, 1821-1825.	2.9	1
20	A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. <i>Advances in Therapy</i> , 2019, 36, 1190-1199.	2.9	7
21	Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1706-1714.	4.4	3
22	Cost-Effectiveness Of The SQ&sup>Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer Perspective&sup>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 637-649.	1.9	2
23	DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK. <i>Diabetes Therapy</i> , 2018, 9, 1217-1232.	2.5	11
24	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. <i>Value in Health</i> , 2018, 21, 724-731.	0.3	63
25	Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. <i>Diabetes Therapy</i> , 2018, 9, 951-961.	2.5	16
26	Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 357-366.	2.1	4
27	Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. <i>Journal of Medical Economics</i> , 2018, 21, 144-151.	2.1	7
28	Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. <i>Diabetes Therapy</i> , 2018, 9, 87-99.	2.5	4
29	An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. <i>Advances in Therapy</i> , 2018, 35, 2128-2137.	2.9	13
30	Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 217-226.	2.4	6
31	An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 223-229.	1.9	2
32	Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1439-1446.	5.0	11
33	Patient safety during procedural sedation using capnography monitoring: a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, e013402.	1.9	71
34	The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus. <i>Value in Health</i> , 2017, 20, 985-991.	0.3	8
35	A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. <i>Journal of Medical Economics</i> , 2017, 20, 213-220.	2.1	11
36	A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 475-483.	1.9	13

#	ARTICLE	IF	CITATIONS
37	Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant. PLoS ONE, 2016, 11, e0160421.	2.5	63
38	Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients. Advances in Therapy, 2016, 33, 345-356.	2.9	16
39	Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. Drugs - Real World Outcomes, 2016, 3, 61-68.	1.6	6
40	Cost-utility of abiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. Journal of Medical Economics, 2016, 19, 672-683.	2.1	9
41	Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK. Journal of Medical Economics, 2015, 18, 1050-1059.	2.1	10
42	An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices. Expert Opinion on Drug Delivery, 2015, 12, 353-360.	5.0	6
43	Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. Diabetes Research and Clinical Practice, 2015, 109, 95-103.	2.8	5
44	A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. Journal of Medical Economics, 2014, 17, 520-526.	2.1	7
45	Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. Journal of Medical Economics, 2013, 16, 1442-1452.	2.1	25
46	Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK. Diabetes, Obesity and Metabolism, 2013, 15, 121-129.	4.4	25
47	Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK. Journal of Medical Economics, 2013, 16, 249-259.	2.1	3
48	Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis. Medical Devices: Evidence and Research, 2013, 6, 107.	0.8	1
49	A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. Journal of Medical Economics, 2012, 15, 766-775.	2.1	6
50	A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin. Advances in Therapy, 2012, 29, 1051-1066.	2.9	4
51	Long-Acting Insulin Analogs: A Review of Real-World Effectiveness in Patients with Type 2 Diabetes. Current Diabetes Reviews, 2011, 7, 61-74.	1.3	19
52	The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. Journal of Medical Economics, 2011, 14, 36-46.	2.1	16